MedTrace Logo

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

NCT07634510 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-06-10

No results posted yet for this study

Summary

This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia).

Researchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment).

The study will help decide the right dose and understand how this medicine could be used in future treatments.

The main questions this study aims to answer are:

1. Is MWX205 safe after a single dose?
2. How does the body process MWX205?
3. Does MWX205 show any effect on the body related to cholesterol levels?

Conditions

  • Dyslipidemias

Interventions

DRUG

MWX205

Each vial contains 200mg of MWX205 small nucleic acid, with water for injection as the solvent. The excipient, including sodium hydroxide and/or hydrochloric acid, may be added to adjust the pH to 6.5±0.2.

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Shanghai Minwei Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Mohd Naguib bin Mohd Yunos, Dr. · Veritus Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2026-10-26
Completion
2027-11-08

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07634510 on ClinicalTrials.gov